A Review of Brucellosis in Iran: Epidemiology, Risk Factors, Diagnosis, Control, and Prevention

Overview

Journal Iran Biomed J

Specialties Biology
General Medicine

Date 2017 Aug 3

PMID 28766326

Citations 50

Authors

Maryam Golshani

Saeid Buozari

Affiliations

Soon will be listed here.

Abstract

Brucellosis caused by species of Brucella is among the most prevalent zoonoses with the annual incidence of half a million cases globally. Most parts of Iran are endemic for brucellosis, and the annual incidence of the human and animal brucellosis is still high. At present, there is no safe and protective human vaccine against brucellosis, and the only preventive strategy is animal vaccination, which harbors significant disadvantages. Considering the identification of many immunogenic proteins in Brucella, several studies have recently been performed to evaluate the vaccine potency of such antigens as a new subunit vaccine candidate. This review represents an overview of brucellosis in Iran, including epidemiology, transmission routs, diagnosis, and treatment. Moreover, it mainly highlights the history of brucellosis control and prevention in Iran, including eradication programs, vast livestock vaccination programs, and subunit vaccine studies. It also discusses major problems that the country encounters with disease control. In recent years, Persian scientists have focused on evaluating the efficacy of best Brucella immunogens in vivo to introduce a new subunit vaccine. The results of some studies could demonstrate the vaccine potential of some immunogens.

Citing Articles

Role of RB51 vaccine in cow milk contamination of traditional milk sales centers.

Gharekhani J, Hemati Z, Adabi M, Asadi F, Dadar M Trop Anim Health Prod. 2025; 57(2):114.

PMID: 40072655 DOI: 10.1007/s11250-025-04362-2.

Renal manifestations of brucellosis: a case report.

Ghavami Z, Amiri B, Haddad M, Khoroushi F, Abedi F, Elyasi S J Med Case Rep. 2025; 19(1):108.

PMID: 40069802 PMC: 11895139. DOI: 10.1186/s13256-025-05145-x.

Spatial interpolation and spatiotemporal scanning analysis of human brucellosis in mainland China from 2012 to 2018.

Zhao Y, Pan D, Zhang Y, Ma L, Li H, Li J Sci Rep. 2025; 15(1):7403.

PMID: 40032911 PMC: 11876684. DOI: 10.1038/s41598-025-91769-4.

Social network analysis of key stakeholders in Brucellosis prevention in Western Iran.

Behzadifar M, Yarahmadi M, Bakhtiari A, Kargar S, Shahabi S, Azari S Trop Med Health. 2025; 53(1):18.

PMID: 39910632 PMC: 11800574. DOI: 10.1186/s41182-025-00693-w.

Assessing the diversity of zoonotic bacterial agents in rodents and small mammals in Iran.

Rezaie N, Latifian M, Ghasemi A, Mahmoudi A, Baseri N, Omidi A Eur J Public Health. 2025; 35(Supplement_1):i41-i47.

PMID: 39801339 PMC: 11725960. DOI: 10.1093/eurpub/ckae132.

References

von Bargen K, Gorvel J, Salcedo S . Internal affairs: investigating the Brucella intracellular lifestyle. FEMS Microbiol Rev. 2012; 36(3):533-62. DOI: 10.1111/j.1574-6976.2012.00334.x. View

Pappas G . The changing Brucella ecology: novel reservoirs, new threats. Int J Antimicrob Agents. 2010; 36 Suppl 1:S8-11. DOI: 10.1016/j.ijantimicag.2010.06.013. View

Sofian M, Aghakhani A, Velayati A, Banifazl M, Eslamifar A, Ramezani A . Risk factors for human brucellosis in Iran: a case-control study. Int J Infect Dis. 2007; 12(2):157-61. DOI: 10.1016/j.ijid.2007.04.019. View

Ghasemi A, Ranjbar R, Amani J . In silico analysis of chimeric TF, Omp31 and BP26 fragments of Brucella melitensis for development of a multi subunit vaccine candidate. Iran J Basic Med Sci. 2014; 17(3):172-80. PMC: 4016687. View

Refai M . Incidence and control of brucellosis in the Near East region. Vet Microbiol. 2002; 90(1-4):81-110. DOI: 10.1016/s0378-1135(02)00248-1. View

Abkar M, Amani J, Sahebghadam Lotfi A, Nikbakht Brujeni G, Alamian S, Kamali M . Subcutaneous immunization with a novel immunogenic candidate (urease) confers protection against Brucella abortus and Brucella melitensis infections. APMIS. 2015; 123(8):667-75. DOI: 10.1111/apm.12400. View

Golshani M, Rafati S, Nejati-Moheimani M, Ghasemian M, Bouzari S . Comparison of potential protection conferred by three immunization strategies (protein/protein, DNA/DNA, and DNA/protein) against Brucella infection using Omp2b in BALB/c Mice. Vet Microbiol. 2016; 197:47-52. DOI: 10.1016/j.vetmic.2016.10.027. View

Galinska E, Zagorski J . Brucellosis in humans--etiology, diagnostics, clinical forms. Ann Agric Environ Med. 2013; 20(2):233-8. View

Behroozikhah A, Nejad R, Amiri K, Bahonar A . Identification at biovar level of Brucella isolates causing abortion in small ruminants of iran. J Pathog. 2012; 2012:357235. PMC: 3515911. DOI: 10.1155/2012/357235. View

10.

Zeinalian Dastjerdi M, Fadaei Nobari R, Ramazanpour J . Epidemiological features of human brucellosis in central Iran, 2006-2011. Public Health. 2012; 126(12):1058-62. DOI: 10.1016/j.puhe.2012.07.001. View

11.

Golshani M, Rafati S, Nejati-Moheimani M, Pourabdi S, Arsang A, Bouzari S . Protein/Protein, DNA/DNA and DNA/Protein based vaccination strategies using truncated Omp2b against Brucella infection in BALB/c Mice. Int J Med Microbiol. 2017; 307(4-5):249-256. DOI: 10.1016/j.ijmm.2017.03.004. View

12.

Tiller R, Gee J, Frace M, Taylor T, Setubal J, Hoffmaster A . Characterization of novel Brucella strains originating from wild native rodent species in North Queensland, Australia. Appl Environ Microbiol. 2010; 76(17):5837-45. PMC: 2935067. DOI: 10.1128/AEM.00620-10. View

13.

Gwida M, Al Dahouk S, Melzer F, Rosler U, Neubauer H, Tomaso H . Brucellosis - regionally emerging zoonotic disease?. Croat Med J. 2010; 51(4):289-95. PMC: 2931433. DOI: 10.3325/cmj.2010.51.289. View

14.

He Y . Analyses of Brucella pathogenesis, host immunity, and vaccine targets using systems biology and bioinformatics. Front Cell Infect Microbiol. 2012; 2:2. PMC: 3417401. DOI: 10.3389/fcimb.2012.00002. View

15.

Perkins S, Smither S, Atkins H . Towards a Brucella vaccine for humans. FEMS Microbiol Rev. 2010; 34(3):379-94. DOI: 10.1111/j.1574-6976.2010.00211.x. View

16.

Beheshti S, Rezaian G, Azad F, Faghiri Z, Taheri F . Seroprevalence of brucellosis and risk factors related to high risk occupational groups in Kazeroon, South of Iran. Int J Occup Environ Med. 2012; 1(2):62-8. View

17.

Golshani M, Ghasemian M, Gheibi N, Bouzari S . Design, and Expression of a Fusion Protein Encoding L7/L12 and SOmp2b Antigens. Adv Biomed Res. 2018; 7:21. PMC: 5840964. DOI: 10.4103/abr.abr_10_17. View

18.

Pakzad I, Rezaee A, Rasaee M, Tabbaraee B, Delpisheh A . Immunogencity of HSA-L7/L12 (Brucella abortus ribosomal protein) in an animal model. Iran J Immunol. 2009; 6(1):12-21. DOI: IJIv6i1A2. View

19.

Golshani M, Vaeznia N, Sahmani M, Bouzari S . In silico analysis of Brucella abortus Omp2b and in vitro expression of SOmp2b. Clin Exp Vaccine Res. 2016; 5(1):75-82. PMC: 4742603. DOI: 10.7774/cevr.2016.5.1.75. View

20.

Seleem M, Boyle S, Sriranganathan N . Brucellosis: a re-emerging zoonosis. Vet Microbiol. 2009; 140(3-4):392-8. DOI: 10.1016/j.vetmic.2009.06.021. View